At a glance
- Cagrilintide is a long-acting analogue of amylin, a hormone released by pancreatic beta cells alongside insulin. It is studied alone and as the amylin-side component of the investigational CagriSema combination.
- Cagrilintide remains investigational. Human trials concern Novo Nordisk’s defined product and study protocol; they do not make an independently sourced vial an approved medicine or a clinical equivalent.
- Use cagrilintide alone to isolate amylin/calcitonin-receptor signalling before studying a GLP-1 combination.
- Track food-intake, satiety-related, gastric-emptying, and glucose endpoints separately in an appropriate model.
What CAGRILINTIDE is—and what the name does not establish
Cagrilintide is a long-acting analogue of amylin, a hormone released by pancreatic beta cells alongside insulin. It is studied alone and as the amylin-side component of the investigational CagriSema combination.
Cagrilintide engages amylin- and calcitonin-receptor systems involved in satiety, food intake, and gastric-emptying signals. That is a different biological route from GLP-1, which is why researchers study the two separately and together.
Questions to settle before interpreting a result
A useful CAGRILINTIDE study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Use cagrilintide alone to isolate amylin/calcitonin-receptor signalling before studying a GLP-1 combination.
- Track food-intake, satiety-related, gastric-emptying, and glucose endpoints separately in an appropriate model.
- When comparing with semaglutide, keep the distinction between amylin/calcitonin and GLP-1 receptor systems explicit.
How to read the CAGRILINTIDE evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Phase 2 · single compound
- Design
- Dose-responsive clinical activity was reported
- Finding
- A 26-week randomized phase 2 trial compared once-weekly cagrilintide with placebo and liraglutide in adults with overweight or obesity. The results establish a clinical-development signal for that product—not a guaranteed effect for research material.
- Read with care
- Keep the finding attached to the linked study’s exact material, design, population, exposure, and endpoint.
Why compare it
- Design
- Amylin is not another name for GLP-1
- Finding
- Both pathways can influence food-intake and gastric signals, but they use different receptor systems. Cagrilintide is valuable precisely because it lets researchers test the amylin route on its own.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Development context
- Design
- Most current attention is on combinations
- Finding
- CagriSema research asks whether pairing cagrilintide with semaglutide produces complementary effects. A combination result cannot be assigned to cagrilintide alone without component controls.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
Cagrilintide remains investigational. Human trials concern Novo Nordisk’s defined product and study protocol; they do not make an independently sourced vial an approved medicine or a clinical equivalent.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- the peer-reviewed phase 2 trialPeer-reviewed publication · Linked record
A 26-week randomized phase 2 trial compared once-weekly cagrilintide with placebo and liraglutide in adults with overweight or obesity. The results establish a clinical-development signal for that product—not a guaranteed effect for research material. The result remains tied to the exact study material, design, population, and endpoint.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for CAGRILINTIDE
This compound is not currently stocked. Add it to your five-choice catalogue ballot.